Key facts
- DeepWise’s last known valuation is $135.0M (Apr 2018).
- It has raised $111.4M; the latest was Later Stage VC ($68.4M) in Jan 2025.
- Notable investors include Legend Capital, Legend Star, Hongtai Capital Holdings, Dalton Venture, China Reform Holdings Corporation — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for DeepWise
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepWise are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepWise
Developer of artificial intelligence (AI) software in healthcare designed to improve efficiency and diagnostic accuracy. The company's software provides a medical imaging diagnosis system using cutting-edge technology used in early screening and diagnosis of malignant diseases, lung cancer, breast cancer, stroke and child growth and development as well as applications for an image in big data in the cloud, facilitating online reading and consultation of doctors, providing domestic and international healthcare providers with AI and internet-based solutions for disease diagnosis, detection and treatment.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 200
- Website
- deepwise.com/
- Ownership
- Privately Held (backing)
DeepWise doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepWise shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepWise in its N-PORT filings yet. We sweep new filings monthly.